Sankyo prepares to renew research into type 2 diabetes drug

Sankyo is designing a new clinical trial for CS-917 for type 2 diabetes, with plans for a mid-stage study launch in the fourth quarter following discussions with the FDA. The announcement came from Sankyo's drug partner, Metabasis Therapeutics. Sankyo had halted research after seeing the level of lactic acid shoot up to dangerous levels in two patients involved in an earlier trial combining CS-917 and metformin. Researchers say that combination may be contraindicated but that a new trial could look at other combinations safely.

- read this article from the AP for more

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.